Harbour BioMed is a global clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics in oncology and immunological disease areas to address unmet patient’s needs.
We are building a robust pipeline with our integrated Harbour antibody platform, that enable us to develop highly differentiated antibodies against various disease targets with great potency and safety profiles. Our proprietary Harbour Mice® generate fully human monoclonal antibodies in the classical two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon our HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) are capable of delivering tumor killing effects unachievable by combination therapies. Integrated with our single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies.
HBM’s efforts are driven by our vision of delivering “Healthy life · Breakthrough Medicines”. To realize this vision, we have been partnering with global academic institutions, biotechnology and pharmaceutical companies by leveraging our platforms. We have established a strong track record of portfolio includes strategically selected co-development clinical assets and internal innovative NextGen projects to address unmet patient’s need. We also provide technology licensing for our proprietary Harbour antibody technologies to accelerate the industry innovation on antibody therapeutics.
Our proprietary antibody technology platforms Harbour Mice® generate fully human antibodies. The platforms have broad potential for generating both conventional as well as the Next-Gen biologics that are fully human, affinity matured with excellent solubility and developability.
Dry Eye Disease
HBM9022(AbbVie; Utrecht University; Erasmus MC)
Global License to AbbVie
Melanoma, HCC, RCC & Other Advanced Solid Tumors
Melanoma, HCC, NEC/NET & Other Advanced Solid Tumors
NSCLC & Other Advanced Solid Tumors
Global License to AstraZeneca
Registrational Clinical Trial
PD1 / Chemo
* MG = Myasthenia Gravis
* NMOSD = Neuromyelitis Optica Spectrum Disorder
* ITP = Immune Thrombocytopenic Purpura
* TED = Thyroid Eye Disease
* CIDP = Chronic Inflammatory Demyelinating Polyradiculoneuropathy
* PV = Pemphigus Vulgaris
* HCC = Hepatocellular Carcinoma
* NEN = Neuroendocrine Neoplasms
* NSCLC = Non-Small Cell Lung Cancer
Partnerships are integral to Harbour BioMed's strategy to build a fully integrated biopharmaceutical company. Harbour BioMed has built up global R&D centers within USA, Europe and China.
Harbour BioMed is interested in combining its discovery capabilities, including its own Harbour Mice® (transgenic mice) Platform Technology, for generating fully human antibodies, and its expertise in clinical development, with potential partners’ unique resources and expertise to co-discovery/co-development biotherapeutics.
Utilizing the world renowned Harbour Mice® Platform Technology, Harbour BioMed has discovered many best-in-class, first-in-class therapeutic candidates that are in different stages of development. Out-Licensing of certain programs allows Harbour BioMed to maximize the value of our assets and concentrate on certain programs, while ensuring patients to have access to all potential therapeutics.
Harbour BioMed is interested in acquiring or obtaining regional rights to molecules from other biotech and pharma companies that can address high unmet medical needs to enhance our portfolio and pipeline in the fields of immuno-oncology and immunological diseases.
The Harbour Mice®Platform Technology, which includes both the H2L2 and HCAb transgenic mice platforms, have been widely used by over 40forty companies and academic institutionscenters. The platforms were engineered to produce high quality, highly diverse and fully human antibodies, through natural process of in vivo maturation from carefully selected human immunoglobulin transgenes.
Currently, there are at least 6 antibodies that are generated from our H2L2/HCAb platforms and have entered into human clinical trials. Besides, over 200 therapeutic candidates discovered from the H2L2/HCAb platforms are in pre-clinical study stages.
Combining the Harbour Mice® Platform Technology with academic institutes’ core strengths in early stage research and discovery is an innovative way to rapidly move attractive therapeutic candidates into the next phase of clinical development.
With highly selected partners who have unique knowledge and insights on special diseases or technology areas, we may choose to create joint ventures with them to explore highly innovative programs to address high unmet medical needs. We have initiated a few JV projects with an aim for broad technology and resource pooling and collaboration in the joint discovery, development and commercialization of the assets generated on our Harbour antibody platforms for treatment of rare diseases
Our latest news, provided in real time.Our latest news, provided in real time.